Due to the increasingly in-depth research on m6A-related studies, it has gradually emerged that YTHDF1 can serve as a pivotal therapeutic target in various treatment modalities, including chemotherapy, immunotherapy, treatment with small molecule inhibitors, targeted therapy, and as a positive factor in cancer biomarker identification. This evidence concerns the gene YTHDF1 and cancer.